Segment - Schedule of Segment Reporting Expenses (Details) - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2025	Dec. 31, 2024
Segment Reporting Information [Line Items]
Revenue	$ 0	$ 0
Operating expenses:
Segment loss	156,373	228,365
Reconciliation of segment loss
Interest and other (income) expense, net	(11,416)	(21,085)
Interest expense	2,559	3,024
Loss on extinguishment of debt	1,828	0
Net loss	149,344	210,304
Reportable Segment
Segment Reporting Information [Line Items]
Revenue	0	0
Operating expenses:
Bexotegrast - clinical trial and outside service third party contracting costs	42,410	86,365
Employee-related expenses - research and development (excluding stock-based compensation)	31,551	35,489
General and administrative costs (excluding stock-based compensation)	30,963	35,537
Other segment items	51,449	70,974
Segment loss	156,373	228,365
Reconciliation of segment loss
Interest and other (income) expense, net	(11,416)	(21,085)
Interest expense	2,559	3,024
Loss on extinguishment of debt	1,828	0
Net loss	$ 149,344	$ 210,304